Guggenheim Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $43

Benzinga Newsdesk www.benzinga.com Positive 61.0%

Neg 0% Neu 0% Pos 61%

Guggenheim analyst Vamil Divan initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Buy rating and announces Price Target of $43.